Jing Li, MD
Hematology & Oncology · Winston Salem, NCNPI 1659551604
Payments from drug & device makers
Across 1 payment — averaging $133.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$133
What the payments were for
- Education$133100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 1 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascular Graft$133
How this compares
$133 in reported general payments places this provider in the 5th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 41 | $933,552 |
| XtandiEnzalutamide | 66 | $914,231 |
| RevlimidLenalidomide | 44 | $764,051 |
| IbrancePalbociclib | 21 | $335,877 |
| JakafiRuxolitinib Phosphate | 19 | $299,838 |
| KisqaliRibociclib Succinate | 17 | $279,827 |
| BosulifBosutinib | 12 | $236,976 |
| AfinitorEverolimus | 13 | $227,618 |
| TagrissoOsimertinib Mesylate | 12 | $203,389 |
| Abiraterone Acetate | 82 | $175,040 |
| CalquenceAcalabrutinib Maleate | 11 | $169,107 |
| EliquisApixaban | 189 | $150,218 |
| Sunitinib Malate | 21 | $80,256 |
| XareltoRivaroxaban | 58 | $49,279 |
| Imatinib Mesylate | 19 | $5,033 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Winston Salem
- Matthew WieduwiltWinston Salem$9.5M
- John McKayWinston Salem$2.9M
- Caio Max Rocha LimaWinston Salem$2.6M
- Michael GoodmanWinston Salem$2.3M
- Rakhee VaidyaWinston Salem$2.3M
- Ravi PaluriWinston Salem$2.3M
- Leon Bernal-MizrachiWinston Salem$1.9M
- Michael McCormackWinston Salem$1.7M
- Angela AlistarWinston Salem$1.5M
- William PettyWinston Salem$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.